Table 2. Showing differences between PDL1 expression positive and negative metastatic TNBCs.
PDL1: Programmed death receptor ligand 1; TNBC: Triple-negative breast cancer
| PDL1 negative | PDL1 positive | P-Value | |
| No. of patients | 80 | 38 | |
| Mean age (years) | 48.4 ± 11 | 49.3 ± 17.4 | 0.655 |
| Age group (years) | |||
| <40 | 22 (27.5%) | 4 (10.5%) | 1 |
| 40-50 | 31 (38.8%) | 21 (55.3%) | |
| 50-60 | 13 (16.3%) | 7 (18.4%) | |
| >60 | 14 (17.5%) | 6 (15.8%) | |
| Ki67 index | 50.3 ± 21.2 | 59.2 ± 17.4 | 0.027 |
| Menopausal status | |||
| Premenopausal | 45 (36.3%) | 17 (44.7%) | 0.3 |
| Postmenopausal | 35 (43.87%) | 21 (55.3%) | |
| Ki67 index | |||
| <20 | 17 (21.3%) | 3 (7.9%) | 0.016 |
| 20-40 | 46 (57.5%) | 18 (47.4%) | |
| 40-60 | 5 (6.3%) | 9 (23.7%) | |
| >60 | 12 (15.0%) | 8 (21.1%) | |
| Sidedness | |||
| Left sided | 45 (56%) | 21 (55%) | 1 |
| Right sided | 35 (43.8%) | 17 (43.7%) | |
| Family history | |||
| Absent | 62 (77.5%) | 30 (78.9%) | 1 |
| Present | 18 (22.5%) | 5 (21.1%) |